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Introduction
With the introduction of endobronchial ultrasound 
(EBUS)-guided transbronchial needle aspiration (EBUS-
TBNA) in 2003, bronchoscopists are able to perform 
guided sampling of structures next to the airways (1). 
In the following decade, EBUS-TBNA has become the 
standard of care for lung cancer staging, recommended 
by American College of Chest Physicians (ACCP) as the 
procedure of choice over mediastinoscopy (2,3). As the 
technique for EBUS-TBNA becomes standardized, there 
are new challenges that need to be addressed, specifically in 
the areas of tissue acquisition for molecular testing and for 
the diagnosis of certain conditions, such as lymphoma and 
sarcoidosis.
While initial studies using EBUS-TBNA samples to 
complete molecular analysis demonstrated success rates 
ranging from 83–97%, the increasing demand for tumor 
tissue poses a challenge to specimen handling (4-8). Current 
guidelines suggest that in the setting of mediastinal staging, 
EBUS-TBNA provides adequate material for diagnostic 
purposes with 3 needle passes (3). When molecular profiling 
is needed, additional needle passes may be required, with 
the optimal number of specimens often based on operator 
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judgement and the type of molecular analysis being 
performed. Furthermore, PD-L1 testing on EBUS-TBNA 
samples has not been validated with any of the commercially 
available platforms (9). Moreover, there is evidence to 
suggest that EBUS-TBNA samples PD-L1 status are 
discordant to that of the surgical resected specimen of the 
primary site of lung cancer (10).
The diagnostic yield of EBUS-TBNA for sarcoidosis is 
lower than that for carcinoma (3,11,12). While the diagnosis 
of sarcoidosis can be enhanced with transbronchial and 
endobronchial lung biopsy, these additional steps may 
increase the risk of bleeding and pneumothorax (13-15). 
While the diagnostic yield of EBUS-TBNA for sarcoidosis 
has been reported at greater than 90% in some studies, 
this result may not be representative of practices in which 
experienced cytopathology services are not available. 
The diagnostic yield of EBUS-TBNA for lymphoma has 
been reported to be lower than that for either carcinoma or 
benign conditions such as sarcoidosis. While EBUS-TBNA 
may be adequate for diagnosing relapsed lymphoma, it has 
not performed well with de novo lymphoma (16-18). Non-
Hodgkin’s and Hodgkin’s lymphoma treatment depend on 
specific subtyping and histologic grade. Therefore, definitive 
subtyping is essential for management and requires the 
evaluation of cell morphology, immunophenotype, and 
tissue architecture. 
EBUS-guided intranodal forceps biopsies (EBUS-IFB) 
is a technique in which small miniforceps are passed into 
targeted lymph nodes following EBUS-TBNA needle 
puncture. The material obtained via EBUS-IFB can be 
processed as a histological specimen and has been shown to 
improve the overall diagnostic yield of EBUS procedures 
when combined with TBNA (19-24). All authors of this 
paper routinely perform EBUS-IFB in their respective 
institutions. Here, we describe the technique for EBUS-
IFB in patients with mediastinal and hilar lymphadenopathy 
and discuss indications, contraindications, technique, and 
available literature for the procedure. 
Intranodal forceps biopsy (IFB)
Nomenclature
IFB has been described in the literature as micro- or mini-
forceps biopsy (MFB), transbronchial forceps biopsy 
(TBFB), and transbronchial needle forceps (TBFN) (19-24). 
In this manuscript, we use the term IFB to describe the 
procedure, and propose that this more accurately reflects 
the procedural elements of obtaining forceps biopsy 
specimens from within a targeted lymph node.
Equipment 
EBUS-IFB is performed utilizing a standard EBUS 
bronchoscope, TBNA needle and 1.0-mm miniforceps 
(Figure 1). While 22-gauge needles have been used for 
TBNA in most EBUS-IFB procedures in the literature, 
others have reported success using 19-, 21- and even 
25-gauge EBUS-TBNA needles. White light bronchoscopy 
is performed initially using a conventional bronchoscope for 
airway inspection as per routine clinical practice.
Technique
Following EBUS-TBNA, the airway mucosa is punctured 
4 to 5 times under ultrasound guidance using the EBUS-
TBNA needle. This creates a defect in the airway mucosa 
as well as a tract for introduction of miniforceps into the 
targeted lymph node. With the EBUS bronchoscope in 
steady position, the aspiration needle is withdrawn from 
the working channel and the miniforceps advanced into 
the target under EBUS guidance. Direct endoscopic 
visualization of the mucosal puncture site is often not 
possible and therefore may not be a reliable landmark 
for miniforceps insertion. To facilitate miniforceps 
insertion into the lymph node, the operator must maintain 
a consistent EBUS image of the lymph node to avoid 
any rotational or cranial/caudal deviation of the EBUS 
bronchoscope that may result in misalignment of the 
miniforceps to the mucosal puncture site (Figure 2). In 
some cases, a needle tract will be created during TBNA 
puncture which may be used as a reference to guide 
miniforceps insertion; alternatively, intranodal landmarks 
such as hyper or hypoechoic spots may also be used as 
landmarks to assist with guiding the miniforceps into the 
lymph node. It may be advisable to begin miniforceps 
insertion slightly proximal to the target tract as the 
miniforceps may slide along the mucosa prior to entering 
the mucosal defect of the target tract. If a 19-gauge needle 
is used, the needle entry alone should create a tract of 
sufficient size for advancing the miniforceps into the target. 
Once inside the target lesion, the miniforceps are opened 
and biopsy specimens are taken under continuous EBUS 
surveillance (Figure 3).
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Specimen handling
Specimens obtained using EBUS-TBNA are processed per 
institutional protocol for cytological specimens. EBUS-
IFB biopsies should be processed as histology specimens 
(Figure 4). Samples are placed into formalin solution for 
permanent fixation or into saline for culture. Frozen section 
can be performed if intraprocedural feedback is desired and 
rapid on-site evaluation of EBUS-TBNA specimens is not 
available (Figure 5). Touch preparations can be done with 
IFB specimens for immediate on-site evaluation, though 
this practice is highly variable amongst institutions. Due to 
the relatively small size of IFB specimens, efforts should be 
placed on tissue conservation. It is advisable to solicit input 
Figure 1 Comparison of miniforceps and regular pulmonary forceps. (A) Miniforceps and regular spiked pulmonary forceps in closed 
position; (B) miniforceps and regular spiked pulmonary forceps in open position; (C) comparison of the length of miniforceps verses regular 
spiked pulmonary forceps. 
Figure 2 EBUS-IFB procedure (25). EBUS, endobronchial 
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from institutional cytologists and pathologists regarding the 
preferred manner in which specimens are processed. 
Indications
EBUS-IFB is complementary to traditional EBUS-
TBNA, and is performed following specimen collection 
with EBUS-TBNA. EBUS-IFB may be performed in any 
clinical scenario in which additional tissue is requested for 
purposes such as molecular marker analysis or to assist with 
making a diagnosis of centrally located thoracic processes 
that are amenable to EBUS-TBNA. EBUS-IFB provides 
histology specimens and therefore may be used in cases 
where “core” biopsy specimens are desired. All mediastinal 
and hilar lymph node stations accessible via EBUS-TBNA 
are accessible using EBUS-IFB. 
Contraindications
Contraindications to EBUS-IFB are similar to that of EBUS-
TBNA, generally related to patient’s fitness to undergo 
bronchoscopy as well as to tolerate moderate sedation or 
general anesthesia. Procedures should be avoided in patients 
at high risk for pulmonary and cardiovascular decompensation 
(i.e., severe refractory hypoxemia, hypotension, and 
arrhythmias), bleeding (i.e., systemic anticoagulation and 
thrombocytopenia), in those who are unable to give informed 
consent, and in those who have had adverse reactions to 
Figure 3 Endobronchial view and ultrasound view. (A) Endobronchial view with microforceps extended out of the working channel. 
Blue arrow is indicating the mucosal defect made by TBNA; (B) miniforceps inserted into the bronchial airway wall; (C) endobronchial 
ultrasound view of the miniforceps in the lymph node; (D) endobronchial ultrasound view of the opening and advancing of miniforceps in 
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Figure 4 Cytology of EBUS-TBNA and histology of EBUS-IFB. (A) Low magnification (H&E stain, 10×) of EBUS-TBNA 25G aspiration; 
(B) high magnification (H&E stain, 40×) of EBUS-TBNA 25G aspiration; (C) low magnification (H&E stain, 10×) of EBUS-IFB; (D) 
high magnification (H&E stain, 40×) of EBUS-IFB. Diagnosis was a renal cell carcinoma. EBUS, endobronchial ultrasound; TBNA, 
transbronchial needle aspiration; IFB, intranodal forceps biopsy; EBUS-TBNA, EBUS-guided TBNA; EBUS-IFB, EBUS-guided IFB. 
Figure 5 Histology of EBUS-TBNA and EBUS-IFB. (A) Low magnification (H&E stain, 10×) of EBUS-TBNA 19G aspiration; (B) 
high magnification (H&E stain, 40×) of EBUS-TBNA 19G aspiration; (C) low magnification (H&E stain, 10×) of EBUS-IFB; (D) high 
magnification (H&E stain, 40×) of EBUS-IFB. Diagnosis was squamous cell lung cancer. EBUS, endobronchial ultrasound; TBNA, 
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anesthesia. As with EBUS-TBNA, systemic anticoagulation 
should be discontinued prior to procedures if possible.
Safety
As a complementary procedure to EBUS-TBNA, EBUS-
IFB does not significantly affect the safety profile or 
workflow of bronchoscopy procedures. Of approximately 
300 EBUS-IFB procedures in published literature, the 
overall complication rate is 1.5%, which is comparable to 
the complication rate associated with EBUS-TBNA. Three 
patients experienced bleeding, controlled locally without 
the need for transfusion and no deaths have been associated 
with the procedure. Management of bleeding from EBUS-
IFB is no different than that with EBUS-TBNA. Often, 
observation alone allows enough time for bleeding to stop. 
If needed, EBUS scope balloon can be used to occlude 
the entry point in the airway wall and provide temporary 
balloon tamponade to stop bleeding. Antimicrobial 
prophylaxis has not been thoroughly evaluated and practice 
varies across centers. The addition of EBUS-IFB does not 
significantly prolong procedure time, adding on average 
less than 4 minutes to EBUS-TBNA procedures in one 
publication (21). While pneumomediastinum has been 
reported with EBUS-TBNA, we do not recommend routine 
use of CT scans in assessment, as most are self-limiting and 
will resolve without intervention. 
Clinical evidence
IFB was first performed without EBUS guidance in 
an effort to increase diagnostic yield when paired with 
conventional TBNA (19). Oki and colleagues performed 
procedures on 22 consecutive patients with enlarged 
subcarinal lymph nodes using a 19-gauge TBNA needle 
and 1.15-mm miniforceps without ultrasound guidance. 
Diagnostic tissue was obtained by IFB in 3 patients in which 
TBNA was non-diagnostic. There was a single case of 
pneumomediastinum (19). In 2008, Herth et al. reported 
on the safety and efficacy of obtaining histologic specimens 
from subcarinal lesions larger than 2.5 cm using EBUS-
TBNA and EBUS-IFB (20).  Seventy-five patients 
underwent EBUS-TBNA with 22-gauge needle, followed 
by needle puncture using a 19-gauge needle through 
a conventional bronchoscope. IFB was subsequently 
performed through the defect made by the 19-gauge needle 
using EBUS guidance, and all procedures were performed 
under general anesthesia through a rigid bronchoscope. A 
specific diagnosis was made in 36% of patients using the 
22-gauge needle, 49% with the 19-gauge needle, and 88% 
with the IFB. The increase in diagnostic yield with IFB 
was most pronounced in patients with sarcoidosis (88% vs. 
36%, P=0.001) and lymphoma (81% vs. 35%, P=0.038), 
and no complications were noted (20). In 2011, Chrissian 
and colleagues prospectively evaluated EBUS-TBNA and 
EBUS-IFB in 74 lymph node stations in 50 patients. The 
overall diagnostic yield was 81% and 91%, for EBUS-
TBNA and EBUS-IFB respectively (21). The overall 
diagnostic yield combining both modalities was 97%, which 
was a statistically significant improvement compared with 
performing EBUS-TBNA alone (P<0.001). There were no 
complications and the addition of EBUS-IFB to EBUS-
TBNA did not significantly lengthen procedure time (21). 
A recent study examined 91 patients who underwent both 
EBUS-TBNA and EBUS-IFB noted that EBUS-IFB 
lead to additional pathologic diagnosis in 16.2% of non-
diagnostic EBUS-TBNA samples, of which 66% were 
non-caseating granulomas (26). Interestingly, Bramley 
et al. reported the combined use of electrocautery knife and 
1.9-mm spiked forceps to obtain lymph node tissue to be safe 
and more effective in detection of granulomatous disease and 
provided larger specimens for clinical studies. However, it 
is worth of noting that EBUS-TBNA had higher sensitivity 
for detecting malignancy than EBUS-cautery assisted TBFB 
(ca-TBFB) (27). Thus, these data overall support the idea 
that EBUS-TBNA and EBUS-IFB are complementary 
techniques in patient management. The relevant studies 
pertaining to EBUS-IFB are summarized in Table 1. 
Discussion
EBUS-TBNA has greatly altered the manner in which lung 
cancer is diagnosed and staged. With advances in cancer 
treatment, bronchoscopists are asked to provide increasing 
amount of material for molecular testing in a safe and 
minimally invasive way. As a complementary technique to 
EBUS-TBNA, EBUS-IFB combines the EBUS guidance 
with miniforceps biopsy to obtain histology specimen for 
additional tissue acquisition. However, in clinical practice, 
EBUS-IFB is underutilized. Several factors contribute 
to the current state. One, lack of familiarity with EBUS-
IFB technique prohibit its use when EBUS-TBNA fails 
to provide adequate samples. Two, with less clinical use, 
physicians often fail to think of the indications that EBUS-
4055Journal of Thoracic Disease, Vol 11, No 9 September 2019
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IFB should be considered. Three, unfamiliarity with the 
equipment and the added cost of the miniforceps are 
prohibitive for adoption in resource poor regions. EBUS-
TBNA has been widely adopted and most bronchoscopists 
are familiar with the technique. As a complementary 
procedure, EBUS-IFB may be well suited for several clinical 
scenarios. 
First, EBUS-IFB may be useful for cases in which 
additional material is required for advanced molecular 
analysis such as EGFR, ALK, PD-L1 testing or next 
generation sequence testing. EBUS-IFB biopsies is 
submitted as core specimens for processing. While some 
institutional practices may be capable of performing these 
assays using cytological specimens obtained by EBUS-
TBNA, this practice appears to be heterogeneous across 
centers at the present time. Submitting core specimens in 
addition to cytology specimens may improve the likelihood 
for specimen adequacy for such tests, thereby obviating 
the need for additional more invasive procedures, such 
as mediastinoscopy or thoracoscopy. Of note, there is a 
19-gauge EBUS needle for core sample acquisition. In a 
recent study comparing 22- to 19-gauge needle for tissue 
acquisition, the authors found similar diagnostic yield, but 
19-gauge had more tissue by weight and more tumor cells 
per sample (28). However, in a separate study, Chaddha 
et al. noted that 19-gauge needle did not provide an 
increase in diagnostic yield and the samples are often more 
bloody (29). From our experience, blood contamination is 
not an issue in EBUS-IFB. Of note, there is no comparison 
of tissue acquisition between 19-gauge needle and IFB, 
which remains an active area for clinical research. Additional 
randomized controlled prospective studies will need to be 
performed to ascertain the added value of the EBUS-IFB in 
the era of molecular testing. 
For diagnostic procedures such as in cases of suspected 
lymphoma or sarcoidosis, combining EBUS-TBNA with 
EBUS-IFB may improve the overall diagnostic yield of 
bronchoscopy, without significantly increasing procedure 
time or complications. While the difference in diagnostic 
yield between EBUS-TBNA and EBUS-IFB was not 
statistically significant (81% vs. 91%, respectively), the 
combined yield of 97% for both procedures represented 
a statistically significant improvement over EBUS-
TBNA alone, suggesting that EBUS-IFB may provide a 
diagnosis in cases where EBUS-TBNA does not (21). This 
study supports the notion that the benefit of EBUS-IFB 
is greatest when used as a complementary procedure to 
EBUS-TBNA, not to be used as a replacement for EBUS-
TBNA. Additionally, the ability to provide a histology 
specimen may enable pathologists to more readily identify 
diagnostic elements in the lymph node (20). This may 
be advantageous in centers with less experience using 
EBUS-TBNA as learning curves for both bronchoscopists 
and cytopathologists have been shown to influence the 
diagnostic yield of procedures (30). Whether EBUS-IFB 
is a superior technique to EBUS-TNBA remains to be 
determined by future studies. 
The influence of EBUS-IFB for lymphoma remains 
unclear, due largely to the relatively small sample sizes 
reported in available literature. Herth et al. reported in 75 
patients an overall improvement in diagnostic yield using 
EBUS-IFB, which was most pronounced in lymphoma cases 
(81% vs. 35%, P=0.038) (20). In a separate study, EBUS-
IFB provided diagnosis of lymphoma in 4 of 4 (100%) 
lymph nodes compared to 0 of 4 lymph nodes using EBUS-
TBNA (1 Hodgkin’s lymphoma and 3 non-Hodgkin’s 
lymphoma) despite the use of flow cytometry in all cases. All 
miniforceps samples were adequate to guide management 
and all cases of lymphoma were new diagnoses (21). In 
a recent study, EBUS-TBNA was able to diagnose and 
subtype lymphoma in 67% (95% CI, 0.45–0.88) of patients 
with de novo lymphoma and 81% (95% CI, 0.70–0.91) with 
relapsed lymphoma (31). Taken these studies together, 
in cases of suspected lymphoma, EBUS-IFB should be 
considered in addition to EBUS-TBNA (Figure 6A,B).
EBUS-IFB was initially proposed as a method to improve 
the overall diagnostic yield of bronchoscopy procedures. 
While the yield of EBUS-TBNA remains excellent for the 
diagnosis of carcinoma, challenges remain with increased 
demand for additional tissue for advanced genetic testing 
as well as the need to improve diagnostic yields for certain 
conditions such as lymphoma, sarcoid, and infection 
(Figure 6C,D). The bronchoscopists are faced with question 
of how to accomplish additional tissue acquisition more 
effectively, efficiently and safely using a minimally invasive 
technique. We propose that EBUS-IFB be considered 
for such instances and suggest that, when combined with 
EBUS-TBNA, this technique may improve the overall 
utility of bronchoscopy to provide diagnostic, staging and 
specimen acquisition. 
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